QIAGEN’s QuantiFERON-TB test chosen for use in England tender
Dec 01 2015

QIAGEN’s QuantiFERON-TB test chosen for use in England tender

Modern gold standard test to be used as part of national TB control strategy

Hilden, Germany, December 1, 2015 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that its QuantiFERON-TB Gold Plus test – the modern gold standard for latent tuberculosis (TB) detection – has been chosen for use in tenders initiated by the National Health System (NHS) in England as part of its national TB control initiatives.

Compared to other European countries, the incidence of TB in the United Kingdom has remained high, and the country has a rate four times as high as in the United States, according to NHS England. The majority of these TB cases are the result of “reactivation” of latent TB, an asymptomatic phase of TB that can last for years. Latent TB can be detected using QuantiFERON-TB Gold, an interferon gamma release assay (IGRA) that requires a small blood sample and can provide results within 24 hours. Those who are found to have latent TB are usually treated with antibiotics to prevent active TB disease in the future.

The tender was not awarded to a specific test, but to laboratories performing tests as a service. QIAGEN currently anticipates supplying around 60% of the total annual test volumes in this tender. QuantiFERON-TB Gold Plus is the leading modern latent TB test with high market shares around the world – and about 80% market share in Europe. The NHS tender results showed six QIAGEN customers who offer the QuantiFERON-TB Gold Plus test were chosen for various regions across the country which amounted to over 80% of the testing volume. These include QIAGEN customers being designated as two of the three providers chosen for each of the largest regions (London and the West Midlands), with these two regions representing approximately 70% of the total annual national testing volume. Two additional QIAGEN customers were chosen as the sole tender winners in two other regions that together represent 10% of the total annual national test volumes. A domestic service laboratory company was the only other participant to be awarded portions of the tender with a service based on an own competing IGRA test other than QuantiFERON TB Gold Plus. The tuberculin skin test was excluded from the tender.

“TB remains one of the most contagious and prevalent diseases in the world, reaching record levels not only in developing countries, but also in England”, said Dr. Masae Kawamura, M.D., QIAGEN’s Senior Director, Medical and Scientific Affairs.QuantiFERON-TB Gold Plus is the industry-leading IGRA that has been chosen in numerous national integrated TB control programs. Together with our partners we are proud to be working closely with public health authorities across England and around the world to stem the tide of rising TB cases.”


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2015, QIAGEN employed approximately 4,500 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Share this page